Literature DB >> 11895373

Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling.

Elizabeth S McDonald1, Anthony J Windebank.   

Abstract

Cisplatin causes apoptosis of DRG neurons in vitro and in vivo that can be prevented by high dose NGF. Design of a neuronal rescue strategy for patients receiving cisplatin will be facilitated by knowledge of the mechanism by which cisplatin causes DRG death. Inhibition of the fas receptor/ligand interaction prevents apoptosis in certain cancer cell lines treated with DNA damaging agents, including cisplatin. We demonstrated that killing curves from mice lacking a functional fas receptor and wild-type controls were not different over a wide range of therapeutically relevant concentrations. However, cisplatin treatment of DRG caused redistribution of cytosolic bax and mitochondrial release of cytochrome c. Bax redistribution was prevented by high dose NGF. This demonstrates for the first time that cisplatin does not signal for death via the fas pathway, but it does initiate the mitochondrial stress pathway in neurons and that NGF blocks death upstream of bax redistribution. (c)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895373     DOI: 10.1006/nbdi.2001.0468

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  44 in total

1.  Drosophila melanogaster: a new model to study cisplatin-induced neurotoxicity.

Authors:  Jewel L Podratz; Nathan P Staff; Dara Froemel; Anna Wallner; Florian Wabnig; Allan J Bieber; Amy Tang; Anthony J Windebank
Journal:  Neurobiol Dis       Date:  2011-04-15       Impact factor: 5.996

2.  Alpha-lipoic acid and frataxin: a new indication for an old antioxidant?

Authors:  James W Russell
Journal:  Exp Neurol       Date:  2009-04-15       Impact factor: 5.330

Review 3.  Peripheral neuropathy in children and adolescents treated for cancer.

Authors:  Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness
Journal:  Lancet Child Adolesc Health       Date:  2018-09-01

4.  Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.

Authors:  Cassandra Johnson; Vernon S Pankratz; Ana I Velazquez; Jeremiah A Aakre; Charles L Loprinzi; Nathan P Staff; Anthony J Windebank; Ping Yang
Journal:  J Neurol Sci       Date:  2015-01-05       Impact factor: 3.181

Review 5.  Toxic Peripheral Neuropathies: Agents and Mechanisms.

Authors:  William M Valentine
Journal:  Toxicol Pathol       Date:  2019-06-10       Impact factor: 1.902

Review 6.  Chemotherapy-induced peripheral neuropathy: A current review.

Authors:  Nathan P Staff; Anna Grisold; Wolfgang Grisold; Anthony J Windebank
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

7.  Naringin Abrogates Cisplatin-Induced Cognitive Deficits and Cholinergic Dysfunction Through the Down-Regulation of AChE Expression and iNOS Signaling Pathways in Hippocampus of Aged Rats.

Authors:  Yassine Chtourou; Brahim Gargouri; Mohammed Kebieche; Hamadi Fetoui
Journal:  J Mol Neurosci       Date:  2015-04-21       Impact factor: 3.444

Review 8.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 9.  Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.

Authors:  Allyson J Ocean; Linda T Vahdat
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 10.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.